OncoMatch/Clinical Trials/NCT06210815
A Study of HLX42 in Advanced/Metastatic Solid Tumors
Is NCT06210815 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HLX42 for solid tumor and nsclc.
Treatment: HLX42 — This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration
Kidney function
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration
Liver function
adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration; for patients with hepatocellular carcinoma, Child-Pugh score must be A
Adequate organ functions as confirmed by laboratory tests within 7 days prior to the first administration of the investigational product; For patients with hepatocellular carcinoma, Child-Pugh score must be A
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify